Abstract
Objective: Perform a systematic literature review on how SGLT-2 Inhibitors (iSGLT2) act on the cardiovascular and renal systems and its benefits for patients with Type 2 Diabetes Mellitus (T2D) and Heart Failure (HF). Methods: Articles were selected from the Medline® database contained in the Pubmed®. 248 articles were found, 32 of which were selected for preliminary analysis through the following filters: “Full Text” ; “Clinical Trial” and “Randomized Controlled Trial”. After complete reading, 8 studies were selected for analysis and discussion of their results. Results: Among the studies, all showed reduction in time of hospitalization or death due to HF. Seven studies also demonstrated such benefits for other cardiovascular diseases in patients using iSGLT2. Conclusion: We conclude that iSGLT2 presents benefits for patients with both HF and DM2, such as decreased blood glucose, HbA1c levels, weight and preload, resulting in reduced hospitalization or death due to HF and other cardiovascular diseases.